Inhibikase Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

Marketable Securities

Marketable Securities

6 Months Ended

Jun. 30, 2025

Investments, Debt and Equity Securities [Abstract]

Marketable securities consisted of the following as of:


June 30, 2025	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	9,926,044	$	—	$	(2,944	)	$	9,923,100
Total	$	9,926,044	$	—	$	(2,944	)	$	9,923,100


December 31, 2024	Amortized Cost		Unrealized Gain		Unrealized Loss			Fair Value
Marketable securities, available-for-sale:
U.S. Treasury obligations	$	41,090,197	$	—	$	(37,248	)	$	41,052,949
Total	$	41,090,197	$	—	$	(37,248	)	$	41,052,949

As of June 30, 2025, the Company held one U.S. Treasury debt security that was in an unrealized loss position totaling $2,944. As of December 31, 2024, the Company held seven U.S. Treasury debt securities that were in an unrealized loss position totaling

$37,248. All U.S. Treasury obligations were due to mature in less than one year for the period and year ended June 30, 2025 and December 31, 2024, respectively.

The Company received proceeds of $31.4 million from maturities of marketable securities for the six months ended June 30, 2025. The Company received proceeds of $23.5 million from maturities of marketable securities for the year ended December 31, 2024. The Company did not realize any gains or losses from maturities of marketable securities for the period ended June 30, 2025 or the year ended December 31, 2024.